Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions
Cynthia Mark1, Jin Sun Lee1, Xiaojiang Cui2
1Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Abstract:
Antibody drug conjugates (ADCs) are novel medications that combine monoclonal antibodies with cytotoxic payloads, enabling the selective delivery of potent drugs to cancer cells expressing specific surface antigens. This targeted strategy seeks to optimize treatment effectiveness while reducing the risk of systemic toxicity, distinguishing ADCs from conventional chemotherapy. The rapid growth in ADC research has led to numerous developments and approvals for cancer treatment, with significant impacts on the management of breast cancer. ADCs like T-DXd for HER2-low disease and sacituzumab govitecan for triple negative breast cancer (TNBC) have provided valuable options for challenging subtypes of breast cancer. However, essential questions still need to be addressed, including the optimal order of ADCs amidst the growing number of newly developed ones and strategies to overcome resistance mechanisms. Preclinical studies have shed light on potential resistance mechanisms, emphasizing the potential benefit of combinational approaches with other agents such as immune checkpoint inhibitors (ICIs) and targeted tyrosine kinase inhibitors (TKIs) to enhance treatment effectiveness. Additionally, personalized approaches based on molecular profiling hold promise in tailoring ADC treatments to individual tumors, identifying unique molecular markers for each patient to optimize treatment efficacy while minimizing side effects.
Insights
Antibody drug conjugates (ADCs) offer targeted cancer therapy by linking antibodies to drugs. Research is exploring optimal sequencing and overcoming resistance for improved breast cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining targeted antibody delivery with potent cytotoxic agents.
- ADCs aim to enhance treatment efficacy by selectively targeting cancer cells while minimizing systemic toxicity compared to traditional chemotherapy.
Purpose of the Study:
- To review the current landscape of Antibody drug conjugates (ADCs) in cancer treatment, particularly breast cancer.
- To address key challenges including optimal sequencing of ADCs and overcoming treatment resistance.
- To explore novel therapeutic strategies, including combination therapies and personalized medicine approaches.
Main Methods:
- Review of recent clinical developments and preclinical research in Antibody drug conjugates (ADCs).
- Analysis of emerging resistance mechanisms and potential strategies to overcome them.
- Exploration of personalized medicine and molecular profiling for tailored ADC selection.
Main Results:
- ADCs such as T-DXd and sacituzumab govitecan have shown significant impact in treating specific breast cancer subtypes (HER2-low and triple-negative breast cancer).
- Preclinical data suggest combinational approaches with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) may enhance ADC effectiveness.
- Personalized treatment strategies based on molecular profiling show promise for optimizing ADC therapy.
Conclusions:
- Antibody drug conjugates (ADCs) are revolutionizing cancer care, offering new hope for challenging malignancies like breast cancer.
- Further research is crucial to establish optimal treatment sequencing and combination strategies to overcome resistance.
- Personalized medicine holds the key to maximizing ADC benefits and minimizing patient-specific side effects.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...